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A window of opportunity for immune responses to extinguish human immunodeficiency virus type 1 (HIV-1)
exists from the moment of transmission through establishment of the latent pool of HIV-1-infected cells. A critical
time to study the initial immune responses to the transmitted/founder virus is the eclipse phase of HIV-1 infection
(time from transmission to the first appearance of plasma virus), but, to date, this period has been logistically
difficult to analyze. To probe B-cell responses immediately following HIV-1 transmission, we have determined
envelope-specific antibody responses to autologous and consensus Envs in plasma donors from the United States
for whom frequent plasma samples were available at time points immediately before, during, and after HIV-1
plasma viral load (VL) ramp-up in acute infection, and we have modeled the antibody effect on the kinetics of
plasma viremia. The first detectable B-cell response was in the form of immune complexes 8 days after plasma virus
detection, whereas the first free plasma anti-HIV-1 antibody was to gp41 and appeared 13 days after the appearance
of plasma virus. In contrast, envelope gp120-specific antibodies were delayed an additional 14 days. Mathematical
modeling of the earliest viral dynamics was performed to determine the impact of antibody on HIV replication in
vivo as assessed by plasma VL. Including the initial anti-gp41 immunoglobulin G (IgG), IgM, or both responses in
the model did not significantly impact the early dynamics of plasma VL. These results demonstrate that the first
IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on
acute-phase viremia at the timing and magnitude that they occur in natural infection.
The development of a preventive human immunodeficiency
virus type 1 (HIV-1) vaccine is a global priority (12). A major
roadblock in development of a preventive HIV-1 vaccine is the
inability to induce protective antibodies by vaccines or natural
infection. Studies in nonhuman primates have demonstrated
that passive infusion of broadly neutralizing anti-HIV-1 mono-
clonal antibodies (MAbs) prevents infection by simian-human
immunodeficiency viruses (29, 41, 64). Thus, if sufficiently high
levels of broadly neutralizing antibodies were present at the
time of transmission, protection from HIV-1 infection might
be possible. However, to date there is no immunogen formu-
lation that consistently induces broadly neutralizing anti-Env
antibodies. Moreover, autologous neutralizing antibody re-
sponses do not occur until months after transmission (1, 24, 50,
60). The window of opportunity during which a protective
antibody might extinguish HIV-1 after the initial transmission
event is uncertain but is likely to be limited to the period of
time prior to establishment of the latent pool of HIV-1-in-
fected CD4 T cells (34, 61). Although viral latency is certainly
established at the time of seroconversion (6), it may be as early
as a few days after transmission (18).
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An important obstacle to the development of an effective
HIV vaccine is the inability to induce antibodies that neutralize
primary HIV-1 strains across all genetic subtypes (17, 42).
While multiple forms of HIV-1 envelope-based vaccines ex-
press epitopes to which rare, broadly neutralizing human
MAbs bind (i.e., Envs are antigenic), these vaccines have not
been immunogenic and have failed to induce broadly neutral-
izing antibodies against the gp120 CD4 binding site shown to
involved in neutralization breadth (38), the membrane proxi-
mal external region (MPER) of gp41 (44, 48), or against gp120
carbohydrate Env antigens (51) in animals or humans.
HIV-1 seroconversion has been reported to occur over a
wide range of times when estimated from the onset of clinical
acute HIV-1 infection (AHI) (5, 30, 45); however, the timing of
seroconversion of HIV antibodies of particular specificities
and isotypes has not been precisely quantified relative to the
first time of detectable plasma viremia. Anti-HIV-1 immuno-
globulin M (IgM) reactive with virus-infected cells has been
detected during the course of AHI (10, 11), but the timing of
these antibodies and the presence of IgM-virion immune com-
plexes relative to the first detection of viral RNA in AHI have
yet to be defined. It is known that autologous neutralizing
antibodies arise only months after the first appearance of HIV-
specific antibodies (1, 24, 50, 60). Critical questions for under-
standing the role of early HIV-1 antibodies in the control of
HIV-1 are, first, what are the nature and timing of the earliest
anti-HIV-1 antibodies and, second, what are the contributions
of these antibodies in the control of viral replication after
transmission?
In this study, we have investigated the timing of specific
anti-envelope (Env) antibody responses from the eclipse phase
(time between transmission and detectable viremia) (19)
through 6 to 12 months of established infection and modeled
the effect of B-cell responses on control of initial plasma vire-
mia. We show that the earliest detectable antibodies to HIV-1
are in the form of virion-antibody immune complexes followed
5 days later by free anti-gp41 IgM plasma antibodies. Mathe-
matical modeling of viral dynamics suggested that the initial
Env gp41 IgM and IgG antibody responses had little effect on
control of initial viral replication.
MATERIALS AND METHODS
Subjects studied. A subset of subjects from four different acute-infection
cohorts were examined: 21 plasma donors, 12 AHI subjects from the Trinidad
cohort (clade B), 14 AHI subjects from the Centre for the AIDS Programme of
Research in South Africa ([CAPRISA] clade C) cohort, and 10 AHI subjects
from the CHAVI 001 acute infection cohort.
Viral load (VL) testing. Plasma viral RNA was measured by Quest Diagnostics
(HIV-1 RNA PCR Ultra; Lyndhurst, NJ).
Antigens used in antibody binding assays. The antigens used for direct antibody
binding assays were as follows: group M consensus Env CON-S gp140, consensus B
gp140, and clade B wild-type IIIB, JRFL, and 89.6 Env gp120s (produced by either
recombinant vaccinia [39] or 293T transfection). In addition, the following peptides
(Primm Biotech Inc, Cambridge, MA) were used: SP400 (gp41 immunodominant
region, RVLAVERYLRDQQLLGIWGCSGKLICTTAVPWNASWSNKSLNKI),
SP62 (gp41 MPER, QQEKNEQELLELDKWASLWN), 4E10 P (SLWNWFNITN
WLWYIK), consensus B V3 gp120 region (TRPNNNTRKSIHIGPGRAFYTTGE
IIGDIRQAH), and consensus M V3 CON-S gp120 region (TRPNNNTRKSIRIG
PGQAFYATGDIIGDIRQAH). Acute HIV-1 envelope gene sequences were
derived from subtype B acute HIV-1-infected individuals (subjects 6246, 6240, and
9021) by single-genome amplification (35). To produce recombinant soluble gp140
proteins, a gp140 env gene construct named gp140C was designed, in which the
transmembrane and cytoplasmic domains of HIV-1 Env were deleted and two
critical Arg residues in the gp120-gp41 cleavage site were replaced with two Glu
residues. All four gp140C env genes were codon optimized by employing the codon
usage of highly expressed human housekeeping genes, synthesized de novo (Blue
Heron Biotechnology, Bothell, WA) and cloned into pcDNA3.1/Hygro expression
plasmid (Invitrogen, Carlsbad, CA) using standard molecular technology. Recom-
binant HIV-1 gp140C Env proteins were produced in 293T cells by transient trans-
fection with the resulting plasmids and purified by Galanthus nivalis lectin-agarose
(Vector Labs, Burlingame, CA) column chromatography (39). Autologous V3 pep-
tides were made from these same Envs.
Antibody assay criteria. The positivity criterion per antigen per antibody
isotype was determined by screening 30 seronegative subjects. A standardized
HIV-positive (HIV) control was titrated on each assay (tracked with a Levy-
Jennings plot with acceptance of titer only within 3 standard deviations of the
mean), and the average optical density (OD) was plotted as a function of serum
dilution to determine antibody titer using a four-parameter logistic equation
(SoftMaxPro, Molecular Devices). The coefficient of variation per sample is
15%. Two negative sera and two HIV control sera were included in each
assay to ensure specificity and for maintaining consistency and reproducibility
between assays. To ensure the integrity of raw data acquisition, data analyses are
electronically tracked (21 CFR part 11).
Direct ELISAs. Direct enzyme-linked immunosorbent assays (ELISAs) were
performed using consensus clade B or envelope glycoproteins, gp41 proteins,
consensus V3 peptides, gp41 immunodominant proteins, and MPER epitopes, as
well as autologous V3 and gp140 Env oligomers. ELISAs were conducted in
96-well ELISA plates (Costar 3369) coated with 0.2 g/well antigen in 0.1 M
sodium bicarbonate and blocked with assay diluent (phosphate-buffered saline
[PBS] containing 4% [wt/vol] whey protein–15% normal goat serum–0.5%
Tween 20–0.05% sodium azide). Serum was incubated for 1 h in twofold serial
dilutions beginning at 1:25, followed by washing with PBS–0.1% Tween 20. A
total of 100 l of alkaline phosphatase-conjugated goat anti-human secondary
antibody (Sigma A9544) was incubated at 1:4,000 for 1 h, washed, and detected
with 100 l of substrate (carbonate-bicarbonate buffer, 2 mM MgCl2, 1 mg/ml
p-NPP [4-nitrophenyl phosphate di(2-amino-2-ethyl-1,3-propanediol) salt]).
Plates were read at 405 nm at 45 min.
Competitive inhibition studies (antibody blocking assays). Competitive inhi-
bition studies (antibody blocking assays) were performed with 1b12 (CD4BS),
2G12 (anti-CHO), and the MPER MAbs 2F5 and 3H11. Ninety-six-well ELISA
plates (Costar 3369) were coated with 0.2 g/well JRFL in 0.1 M sodium bicar-
bonate and blocked with assay diluent (PBS containing 4% [wt/vol] whey pro-
tein–15% normal goat serum–0.5% Tween 20–0.05% sodium azide). All assay
steps were conducted in assay diluent (except the substrate step) and incubated
for 1 h at room temperature (13H11 assay at 37°), followed by washing with
PBS–0.1% Tween 20. Serum was diluted 1:50 and incubated in triplicate wells. A
total of 50 l of biotinylated target MAb was added at the 50% effective con-
centration (determined by direct binding curve of biotinylated MAb to JRFL).
The extent of biotin-MAb binding was detected with streptavidin-alkaline phos-
phatase at 1:1,000 (Promega V5591), followed by substrate (carbonate-bicarbon-
ate buffer, 2 mM MgCl2, 1 mg/ml p-NPP)). Plates were read with a plate reader
at 405 nm and 45 min. Triplicate wells were background subtracted and aver-
aged. Percent inhibition was calculated as follows: 100  (mean OD of triplicate
serum wells/mean OD of no-inhibition control 100.) CD4 binding site blocking
assays were conducted as above, except that 100 l of a saturating concentration
of soluble CD4 (Progenics Pharm Inc.) was incubated between serum and biotin-
MAb incubation steps.
AtheNA assay. Antibody binding to proteins gp160, gp120, p66, p55, gp41, p31,
p24, and p17 was measured on the Luminex platform (Luminex Corporation)
using an AtheNA Multilyte HIV-1 Bead Blot kit (Zeus Scientific catalog number
A71001G) following the kit manufacturer’s protocol.
Cardiolipin and rheumatoid factor assays. Anti-cardiolipin antibody assays
were performed as described previously (2). Assays to measure IgM rheumatoid
factor using IgG antigen were standardized using rheumatoid factor controls
(kindly provided by Judy Fleming, Clinical Immunology Laboratory, Duke Uni-
versity Medical Center).
Isotype binding antibodies. HIV antigens or purified IgM, IgG, and IgA
proteins (used as controls) were precoated overnight onto the wells of microtiter
plates (NUNC) and washed with an automated and calibrated plate washer
(Bio-Tek). The serum/plasma test samples were diluted and incubated with the
antigens bound to the plate. The plates were then washed, and the antigen-
antibody complexes were incubated with isotype-specific anti-human IgG, IgA,
and IgM conjugated to alkaline phosphatase. OD readings were measured using
a VersaMax plate reader (Molecular Devices), and an average OD reading for
each pair of replicates, with the background subtracted, was calculated. For each
test sample, duplicate antigen-containing and non-antigen-containing wells of a
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microtiter plate were scored (i.e., OD of antigen-containing wells  OD of
non-antigen-containing wells). A positive score is defined as an OD value of
0.1, with background subtracted, and also as at least threefold above the
baseline, with a 15% coefficient of variation between replicates. As another level
of validation, in the plasma donor samples we compared the HIV gp41-specific
IgM binding antibody test with that of the third generation Abbott Diagnostics
EIA (enzyme immunoassay; Abbott Park, IL) and found equal sensitivity to the
commercially available kit for the first detection of any antibody response.
Specimen prep for MultiTrap IgG removal. For detection of IgA and IgM
antibodies, IgG was removed using protein G columns. Briefly, plasma was
centrifuged (10,000  g) for 10 min, diluted twofold in dilution buffer, and
filtered in a 1.2-um-pore-size filter plate (Pall AcroPrep). The filtered and di-
luted samples were depleted of IgG using protein G high-performance Multi-
Trap plates (GE, Inc.) according to the manufacturer’s instructions with minor
modifications. IgG removal in the specimens was greater than 90% as assayed by
HIV-specific binding assays.
Customized Luminex assay. A total of 5  106 carboxylated fluorescent beads
(Luminex Corp, Austin, TX) were covalently coupled to 25 g of one of the
purified HIV antigens used in ELISAs and incubated with patient samples at a
1:10 dilution. HIV-specific antibody isotypes were detected with goat anti-human
IgA (Jackson Immunoresearch, West Grove, PA), mouse anti-human IgG
(Southern Biotech, Birmingham, AL), or goat anti-human IgM (Southern Bio-
tech, Birmingham, AL), each conjugated to phycoerythrin, at 4 g/ml. Beads
were then washed and acquired on a Bio-Plex instrument (Bio-Rad, Hercules,
CA). Purified IgM, IgG, and IgA proteins (Sigma) and a constant HIV serum
titration were utilized as positive controls in every assay. Background values
(beads in the absence of detection antibody) and normal human plasma were
utilized as the negative controls. A control for rheumatoid factor for IgM de-
tection was an internal IgG protein standard.
HIV-1 immune complex capture assays. ELISA plates (NUNC) were coated
overnight at 4°C with anti-human IgM or IgG at a concentration of 1 g/ml
diluted in PBS. All subsequent steps were performed at room temperature. After
incubation and washing, coated plates were blocked for 2 h with PBS supple-
mented with 5% fetal bovine serum, 5% milk, and 0.05% Tween. After blocking
and washing, 90 l of undiluted plasma was added to each well and incubated for
90 min, followed by four washes with PBS supplemented with 0.05% Tween. A
total of 200 l of AVL lysis buffer with carrier RNA (Qiagen) was added and
shaken for 15 min, and viral RNA in the lysis was extracted by a Qiagen viral mini
kit. HIV-1 RNA from the virion-antibody complexes was measured by Gag
real-time reverse transcription-PCR. The detection of immune complexes by the
ELISA capture assay was confirmed using protein G column absorption (Protein
G HP column; Pierce, Inc.) to deplete IgG-virion immune complexes. IgG
absorption was performed according the manufacturer’s instructions. Plasma (90
l) was added to the protein G column. After a mixing step and an incubation of
10 min, the column was centrifuged for 1 min at 5,000  g. The presence of
immune complexes was calculated by the percentage of viral RNA input divided
by viral RNA flowthrough, similar to the method by Baron et al. (16). HIV
immune globulin (reagent from the Division of AIDS, NIH) plus HIV-1 NL4-3
pseudotyped virus was the positive control for immune complex capture (81% 
4%), and normal human serum ([NHS]Sigma) or RPMI 1640 medium plus
HIV-1 NL4-3 was the negative control. The cutoff of non-HIV-1-specific capture
(NHS plus NL-43) was 16.2%  0.8%; the background of virus-only control was
6.5%  4.6%.
Complement binding assays. Virus and diluted plasma samples (1:40) were
incubated at 37°C in the presence of 10% NHS (Sigma, St. Louis, MO) as a
source of complement or with 10% heat-inactivated NHS. MT-2 cells, which
express high levels of CR2, were then added, and the virus/cell suspensions were
incubated for 2 h. Unbound virions were removed by successive washes. Bound
virions were disrupted by treatment with 0.5% Triton X and the released p24 was
measured by ELISA. To determine percent binding, the amount of p24 obtained
was divided by the amount of p24 of the original virus after correcting for
complement nonspecific binding (hi NHS).
Neutralizing antibody assays. Antibody-mediated neutralization in the plasma
donor cohort was measured as a function of reductions in luciferase reporter
gene expression after a single round of infection in TZM-bl cells, as described
previously (37). For assay of plasma for 2F- and 4E10-specific neutralizing
antibodies, HIV-2 pseudoviruses expressing HIV-1 2F5 or 4E10 epitopes were
used as described previously (24).
Statistical analyses and methods to classify simultaneous and sequential
kinetics. Statistical analyses were conducted using methods that included mixed-
effects models (55, 58, 59), nonparametric regression (25), a binomial test,
Kaplan-Meier curve, and an accelerated failure time model (13). For all four
cohorts, smoothing spline-based nonparametric regression (25) was performed
to obtain estimates of the VL and antibody curves. For the plasma donor cohort,
where the acute burst of viremia was recorded, we defined an accurate time of
origin (T0) to align different study panels for the joint analyses. For each patient,
the T0 was estimated as a model parameter in the nonlinear mixed-effects model
of the upswing VLs, accounting for censoring at the assay limits of detection (55).
Right-censoring was used in the survival analysis such that data were suspended
for subjects for whom no event occurred during the follow-up period (while the
event could happen at a later time, i.e., to the right in the time scale). Two
subjects were censored because of their short follow-up period (12 days after T0).
For each analyte (e.g., anti-IgA/IgG/IgM gp41 antibody response), data recorded
prior to T0 were fit to a linear mixed-effects model (58) to determine the
background level for that analyte, where the upper 95% prediction limit of a
future response (59) was used as a positivity threshold to define the last negative
observation and the first positive observation. The statistical method of classify-
ing simultaneous and sequential kinetics verified the results obtained from
ELISA calculations based on the positivity criterion.
A Kaplan-Meier estimate was used to describe the distribution of the initial
elevation timing. A two-sided binomial test of relative ranking in elevation timing
between pairs of analytes was performed with a positive difference in timing as
a success and the number of nonzero differences as the number of trials. Ad-
justed P values (q values) were computed to control for the false discovery rate
of multiple testing (54). To assess association between the VLs and antibody
markers in both the plasma donors and CHAVI 001 cohorts, accelerated failure
time models (13) were used to correlate the expansion or decay of the VLs and
the time to initial elevation (subject to censoring), and linear mixed-effects
models (58) were used to correlate the downswing VLs and antibody response
magnitudes over time. Additionally, statistical correlation and linear regression
analyses were performed to identify the plausible association between different
inhibition assays in the Trinidad and CAPRISA cohorts.
Modeling. The following is the target cell-limited model used to mathemati-
cally model the plasma donor VL:
dT
dt
   dT  kVT
dI
dt
 kVT  I (1)
dV
dt
 pI  cV
Cells that are susceptible to HIV infection are termed target cells (T). The model
assumes that target cells are produced at a constant rate, , and die at rate d per
cell. Upon interaction with HIV, these cells become productively infected cells
(I)with infection rate constant k. Infected cells die at per cell rate  and produce
viral particles (virions), V, at rate (p) per infected cell. Virions are assumed to be
cleared at a constant rate, c, per virion.
To incorporate enhanced virion clearance due to opsonization, we replaced
the equation for V(t) in the model above with the following equation:
dV
dt
 pI  c1  	Igt

V (2)
Here, virion clearance is enhanced by a factor (1  	Ig(t)), where Ig(t) is either
the measured concentration of anti-gp41 IgM or anti-gp41 IgG or the total of
both Ig concentrations in plasma. If 	  0, then there is no opsonization effect.
To model the effects of antibody in neutralizing virus, we reduced the infec-
tivity constant k in equation 1 by the factor (1  Ig(t)). Here, if   0 there is
no antibody-mediated viral neutralization. Lastly, to incorporate the possibility
of antibody enhancing the rate of infected cell loss through antibody-dependent
cellular cytotoxicity or complemented mediated lysis, we increased  by the factor
(1   Ig(t)). If   0, there is no enhanced death.
At T0, which we chose as time t  0, the plasma VL by definition is 100
copies/ml. While some CD4 depletion could have occurred by T0, for simplicity
we assume the uninfected cell level is still 106 cells/ml. We estimated the number
of infected cells at T0 as either 1 or 10 cells/ml based on preliminary fits. This low
number of infected cells supports our assumption of little T-cell depletion by T0.
The target cell-limited model as well as the three variants of it that included
antibody effects were fit to VL data of each plasma donor using a spline fit to the
measured anti-gp41 concentrations for Ig(t). Fitting to the VL data was done
using a nonlinear least squares method where loge V from the model was fit to
the loge of the measured VL. An F-test was used to determine whether the target
cell-limited model or one of the three variants fit the data best. For donor 9032
the best-fit target cell-limited model gave an extremely poor fit to the data unless
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we added to the sum of squared residuals a penalty function for not attaining a
maximum at the time the VL was maximum. That is, we add an additional term
to the function to be minimized equal to the square of the difference between the
time the VL was maximum in the data and in the model.
RESULTS
Plasma donor cohort. HIV-1 seroconversion plasma donors
from the United States (clade B) were studied for the earliest
antibody events in HIV-1 infection. These subjects donated
plasma every 3 days, and the plasma units were held for weeks
until tests for HIV-1, hepatitis B, or hepatitis C were com-
pleted (19). Once a donor was found to be positive for an
infectious disease, the plasma sample donations were stopped;
therefore, neither cells nor long-term follow-up of these
plasma donors was available. Analysis of the U.S. plasma do-
nor cohort provided for calculation of the earliest HIV-1 an-
tibody response in relation to a defined point where viral RNA
was first detected at transmission. A time zero (T0) that rep-
resented the initial time at which the VL trajectory crossed the
assay lower limit of detection (100 HIV-1 copies/ml) was es-
tablished to align each donor panel to a single reference time
(Fig. 1A). The start of detectable plasma viremia, T0, is ap-
proximately 10 days (range, 7 to 21 days) (7, 11, 14, 21, 40, 52)
after virus transmission and represents the end of the eclipse
phase of HIV infection. The plasma samples studied from this
cohort had the most frequent sampling for testing within the
first 20 days before and the first 20 days after the start of
detectable viremia (Fig. 1B).
Initial IgG anti-Env responses following transmission. To
ensure that the earliest antibodies were detected, both stan-
dardized ELISAs and more sensitive Luminex quantitative an-
tibody assays were utilized. The lower level of sensitivity for the
ELISAs for measurement of anti-HIV-1 Env IgG was 2.2 ng/
ml, and the lower level of sensitivity of Luminex assays for
measurement of anti-HIV-1 IgG was 0.2 ng/ml. For identifica-
tion of initial antibody responses, we tested autologous, con-
sensus B, and clade B wild-type Envs as antigens. For non-Env
antigens, all antigens were wild-type clade B. To validate that
consensus B Env antigens detected the earliest antibodies and
to determine if earlier antibody responses could be detected
using autologous Env antigens, gp140 and Env gp120 V3 pep-
tides from four plasma donor subjects were produced and
compared with consensus B Envs or V3 peptides for the ability
to detect plasma Env antibodies.
First, using consensus or wild-type clade B Envs, we found
that the earliest detectable anti-Env IgG plasma antibody re-
sponses following HIV-1 transmission were to envelope gp41
and occurred at a median of 13.0 days after T0. Figure 2A
illustrates the earlier timing of the anti-gp41 antibody re-
sponses and the later and more variable timing of the antibody
responses against gp120 (P  0.01). Antibodies to gp41 devel-
oped in 90% of subjects by 18 days (Km estimate is 100%; two
subjects were censored because they were lost to follow-up at
12 days after T0) in contrast to gp120 antibody responses,
which came up in 33% of subjects during the follow-up period
of between 12 and 67 days after T0 studied here (Table 1).
There was no significant difference in the timing of the anti-
gp120 antibody responses when two additional wild-type clade
B gp120 envelope proteins, JRFL and 89.6 gp120 Envs, were
examined (data not shown). Figure 2B shows the median time
of appearance of gp41 and gp120 antibodies compared to time
of appearance of antibodies to HIV-1 p24, p55, p66, p17, and
p31 proteins. Pairwise comparison of the timing of each spec-
ificity of antibody demonstrated that HIV-1 structural compo-
nent antibody timing (anti-Gag) was significantly later than
that of HIV-1 gp41 antibodies.
A summary of the timing of various anti-Env antibody re-
sponses detected in U.S. plasma donors is shown in Table 1.
For the first antibody elicited against gp41, 13/19 (68%) of
gp41 responses included the immunodominant region of gp41,
and 7/7 of the plasma donor initial gp120 included responses
that could be mapped to the V3 loop (i.e., 100% of the plasma
donors that had gp120 antibodies within the first 40 days of
transmission also had V3 antibodies). Antibodies that did not
appear at all in U.S. plasma donor subjects (within 40 days
after T0) were anti-MPER (neutralizing and nonneutralizing)
antibodies, CD4 binding site antibodies (CD4bs), and CD4-
induced antibodies (CD4i). Neutralizing antibodies to the eas-
ily neutralized tier 1 (37) HIV-1 Env pseudoviruses such as
B.SF162 and antibody-dependent cell-mediated virus inhibi-
FIG. 1. (A) VL kinetics of 21 HIV seroconversion plasma donor
panels (eclipse phase clade B infection) were determined. The align-
ment of the subjects was by T0, the first day that VL reached 100
copies/ml. (B) Histogram displaying the total number of samples stud-
ied for each day, relative to the first detectable day of viremia (T0).
Bins represent intervals of 10 days.
12452 TOMARAS ET AL. J. VIROL.
 on O







tion (ADCVI) activity (29) also did not appear within the first
40 days after T0 as well (data not shown). ADCVI has previ-
ously been reported to be present during the later stages of
acute infection, so the time points examined here during acute
viremia in the plasma donor subjects are likely just before the
development of ADCVI (20). As expected, broadly neutraliz-
ing antibodies with specificities similar to the broadly neutral-
izing antibodies 2F5, 4E10, 1b12, and 2G12, as measured by a
competitive ELISA with biotinylated MAbs, also did not ap-
pear during the first 40 days after T0 (not shown).
Analysis of isotype-specific gp41 antibody responses. IgG
antibodies are produced after Ig class switching and are clas-
sically produced after IgM antibodies. We assayed for HIV
Env-specific IgM using Luminex assays with recombinant gp41,
gp120, and consensus B and group M consensus gp140 protein
antigens. As with IgG responses, the first IgM antibody against
Env also targeted only gp41. The median time of rise in HIV-
1-specific IgM antibodies was 13 days post-T0 (range, 5 to 18
days). The custom anti-IgM ELISA utilized in this study was
FIG. 2. (A) Kaplan Meier plot of anti-gp41 and anti-gp120 antibody responses in the eclipse phase clade B plasma donor cohort. The solid line
shows the increasing percentage of the population that develops HIV-specific antibody responses at each time interval following the calculated T0.
The dashed lines indicate the upper and lower point-wise confidence intervals, respectively. (B) Pairwise comparison of the timing of anti-Env
antibody responses compared anti-Gag (p24, p17, and p55) and anti-Pol (p31) responses in the eclipse phase clade B plasma donor cohort. The
solid line (from left to right) indicates the median day of antibody elevation from T0, and the gaps in the line indicate the HIV-specific antibody
responses that group together relative to their time of elevation from T0. The values above the lines are q values for pairwise tests of differences
between adjacent groups of antibody specificities. ns, no statistically significant pairwise difference within the group of antibody specificity. The
median time for appearance of IgG anti-gp41 antibody was 13.5 days (A), while the median time for appearance of IgG gp120 antibody was 28
days (B).











gp41 19 13 (9–18) 12 14
gp140 19 13 (6–17) 12 15
ID gp41 peptidee 13 18 (13–34) 16 —
gp120 7 28 (13–41) 26 —




a Number of plasma donor subjects that showed an elevation during the follow
up period.
b Median time from T0 (the first day viral load reaches 100 copies/ml).
c LCL, lower confidence limit.
d UCL, upper confidence limit. —, upper confidence limit is infinite (eleva-
tions can occur at 67 days from T0).
e ID, immunodominant.
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equally sensitive to the third generation commercial ELISA
(Abbott Anti-HIV-1/2 EIA; Abbott Park, IL) for detection of
the first free HIV-specific antibody. The difference in timing of
first antibody detection between the two assays was not signif-
icant (median difference in days to detection, 0; P value of 0.66,
Wilcoxon signed rank test).
We expressed four autologous gp140 envelopes from four dif-
ferent plasma donor subjects (subjects 6246, 6240, 9021, and
63521) representing the transmitted or founder virus (35) as
gp140C protein oligomers and also studied four subjects with
autologous Env V3 loop peptides as targets for plasma antibody
binding assays. Three of the gp140 Envs were chosen from sub-
jects in whom an antibody response was detected with the con-
sensus Env, while gp140 was expressed from one subject who did
not have a detectable anti-gp41 response. A representative exam-
ple from a single donor against the autologous and consensus
clade B Env for IgM, IgG, and IgA is shown in Fig. 3A to C (see
also Fig. S2 in the supplemental material). We found that, using
both autologous Envs and autologous V3 peptides (not shown),
we could not detect any IgM, IgG, and IgA antibody responses
earlier than those detected using group M consensus Envs or
consensus B V3 peptides (Fig. 3A to C). Interestingly, the gp41
antibody responses were greater in magnitude when tested with
consensus Envs versus autologous envelopes.
We next examined Ig class switching patterns in plasma
donors (15 subjects), four clade B CHAVI 001 subjects, and
three clade B AHI subjects from the Trinidad/Tobago cohort,
where the plasma sampling was sufficiently early to determine
the first appearances of anti-gp41 IgM and IgG (see Materials
and Methods and Fig. S1 in the supplemental material for VL
and timing of samples from the CHAVI 001 and Trinidad/
Tobago acute HIV-1 infection cohorts). Figure 4 shows repre-
sentative subjects with either sequential class switching kinetics
(Fig. 4A) or simultaneous class switching kinetics (Fig. 4B) in
the plasma donor cohort. In both subjects, IgM responses were
transient and decayed over a period of 20 to 40 days, while IgG
responses rose over the same period. Anti-gp41 IgM responses
appeared earlier than IgG responses in 9/22 (41%) of subjects;
however, in 13/22 (59%) of subjects, IgM anti-gp41 was de-
tected at the same time as IgG and IgA anti-gp41 antibodies
(Fig. 4C). We also tested anti-IgM, anti-IgG, and anti-IgA
responses to a gp41 immunodominant peptide in subject 6246
with simultaneous appearance of anti-gp41 IgM, IgG, and IgA
to determine if the simultaneous appearance of the three iso-
types could potentially be due to responses to different gp41
epitopes. We found that anti-immunodominant IgM, IgG, and
IgA were simultaneously detected, demonstrating in this sub-
ject that the simultaneous appearance of antibodies could not
be attributable solely to the development of antibody re-
sponses to multiple gp41 epitopes (data not shown). To deter-
mine if simultaneous IgM, IgA, and IgG antibody responses were
unique to envelope or, rather, occurred in the response to other
HIV-1 proteins, we also determined the pattern of isotype anti-
body responses to p55 Gag. We found that IgM, IgG, and IgA
FIG. 3. Anti-gp41 IgM antibodies are the first detectable HIV antibodies, and autologous gp140-transmitted Env or consensus Env gp140
proteins are equally sensitive for the detection of the first antibody isotypes in HIV infection. IgM antibodies (A), IgG antibodies (B), and IgA
antibodies (C) were detected using either consensus gp140 (ConB) or autologous Env (6246 Env). The asterisk indicates the plasma sample from
which the autologous gp140 Env was derived. The consensus gp160 oligomer detects anti-gp41 antibodies at the same time as autologous gp140
Env oligomers. MFI, mean fluorescence intensity.
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antibodies to p55 Gag were also detected simultaneously in sub-
jects that had simultaneous appearance of IgM, IgG, and IgA
antibodies to gp41 Env (Fig. 4D).
Detection of immune complexes in AHI. We next assayed
panels from U.S. plasma donors for earlier antibody responses
in the form of antibody bound to virions to determine if earlier
antibody was being made and was not in plasma but, rather,
was present only in the form of virion-IgM or -IgG antibody
complexes. In 6/6 of subjects tested with sufficiently high
plasma viral RNA levels, immune complexes containing either
IgG or IgM antibodies bound to virions were detected (Fig. 5).
Immune complexes were detected at a median time of 8 days
(range, 5 to 14 days) after T0. The detection of immune com-
plexes preceded the detection of free antibodies by both com-
mercial ELISA and custom ELISA by a median of 5 days
(range, 5 to 7 days) (Table 2). Virion-antibody complexes were
detected in subjects with either simultaneous or sequential Ig
isotype kinetics, and this suggests that the presence of early
immune complexes likely does not explain the simultaneous
detection of IgM, IgG, and IgA anti-gp41 isotypes.
The detection of IgG immune complexes was confirmed with a
second assay of detection (data not shown) using a protein G
column to capture antibodies bound to virions, followed by lysis of
virions to measure viral RNA. Identical kinetics of the appear-
ance and decline of immune complexes were observed using both
methods for measurement of IgG immune complexes (data not
shown). Taken together, these data suggest earlier production of
anti-virion IgM and IgG on day 8 after T0 and before the appear-
ance of free plasma anti-HIV IgM and IgG. The simultaneous
appearance of both IgM and IgG virion immune complexes either
suggests simultaneous induction of anti-virion IgM and IgG in
these subjects or indicates yet earlier induction of IgM and IgG
antibodies to HIV virion components with specificities that are
not detectable with our current assays. The decline in detection of
immune complexes may be due to clearance by the reticuloendo-
thelial cell system. It is of interest that the detection of these
antibody-virion complexes declines while virus (antigen) and an-
tibody are still present. Further study of the specificities of the
antibodies bound in immune complexes and whether they are
able to alter infectivity by enabling binding to antigen-presenting
cells is under investigation.
AHI anti-gp41 Env antibodies activate complement. A po-
tentially important functional component of antibodies in AHI
is their ability to fix complement. We determined if early anti-
gp41 antibodies were capable of binding serum complement.
Plasmas from six U.S. plasma donors were examined for com-
plement activation/binding to CR2 using human peripheral
blood mononuclear cells cocultured with HIV-1 virions. Com-
plement-activating binding antibodies were present in all pan-
els at every time point that plasma antibodies were detected as
shown in Fig. 3. Moreover, the kinetics of appearance of com-
plement-activating antibodies followed the same kinetics as gp41
FIG. 4. Kinetics of anti-gp41-specific antibody isotypes in acute HIV infection. Representative examples of sequential development (A) and
simultaneous development (B) of early HIV-specific antibody responses are shown. (C) The percentage of patients in each of the three cohorts
that displayed different kinetic patterns. (D) Simultaneous development of Gag-specific antibody responses. Anti-p55 antibodies of the IgM, IgG,
and IgA isotypes were measured for all subjects in the eclipse phase clade B cohort. Subject 12007 could not be aligned to T0 due to the large
interval between the first RNA-positive sample and the last RNA-negative sample. However, the short interval between antibody-positive and
antibody-negative responses enabled measurement of antibody isotype kinetics, so the panel was aligned to T0 as the first RNA-positive sample.
Pt, patient.
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binding antibodies. Both a laboratory-adapted HIV-1 strain
(B.SF162) and an early transmitted virus strain (B.QH0692) were
examined as targets of antibody and complement with similar
results obtained with each virus (Fig. 6).
Polyclonal B-cell activation following HIV-1 transmission in
U.S. plasma donors. HIV-1 Env gp120 has been suggested to
be a polyclonal B-cell activator (3), to bind to VH3 Ig as a
superantigen (23), and to induce polyclonal Ig class switching
(28). Patients with chronic HIV-1 infection have polyclonal
hypergammaglobulinemia (36), and a number of studies have
reported hypergammaglobulinemia in early HIV-1 infection
(47, 56). To examine whether polyclonal B-cell activation oc-
curs during the initial antibody response to HIV-1 transmitted/
founder Env, we measured quantitative IgM, IgG, and IgA
levels on the initial and last plasma samples of the U.S. plasma
donors. There was no significant elevation of IgM, IgG, or IgA
during AHI in plasma donor panels (Fig. 7A). Similarly, the
last plasma sample in each donor panel (range of 25 to 41 days
after T0) was analyzed for the following autoantibodies: cardio-
lipin, SSA/Ro, SSB/La, Sm, RNP, Scl-70, Jo-1, double-
stranded DNA, centromere B, and histones, and all were neg-
ative for all these specificities (data not shown). However, in a
screen for rheumatoid factor autoantibodies (IgM antibodies
that react with IgG) of 19 plasma donor samples and 10
CHAVI 001 acute infection cohort subjects studied, 8/29
(28%) tested positive for rheumatoid factor following HIV-1
FIG. 5. HIV immune complexes produced at a median time of 8.0 days after T0. The detection of immune complexes for patients (Pt) 9015,
12008, 9077, 9079, 9021, and 9076 are aligned to T0 and plotted in comparison to the detection of free antibody (Ab) responses.
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transmission (Fig. 7B), with approximately half of these show-
ing a decline in the level of rheumatoid factor antibody after
initial detection during acute viremia. Thus, in some subjects,
B-cell activation during acute HIV-1 infection can result in
production of the autoantibody, rheumatoid factor (26).
Modeling of the initial gp41 antibody response with acute
VL kinetics and assessment of antibody pressure on viral
sequence evolution. To determine the effects of initial anti-
gp41 antibody responses on control of HIV-1 VL, we used
mathematical modeling of the early viral dynamics. We first
used the target cell-limited model (53), which does not include
any effect of antibody, to analyze the plasma donor VL data
obtained over the first 40 days after T0 for the six donors (6240,
6246, 9032, 9077, 9079, and 12008) for which both complete
VL and antibody data were available over this time period. We
found that for all donors except 9032, the target cell-limited
model gave good agreement with the experimentally deter-
mined VL data (Fig. 8). We then fit to the same data three
variants of this model that included enhanced virion clearance
due to antibody opsonization, antibody-mediated viral neutral-
ization, or antibody-dependent loss of HIV-1-infected cells. In
these models (see Materials and Methods), we included the
measured levels of anti-gp41 IgM, IgG, or the sum of IgM and
IgG in mediating these effects. Anti-gp120-directed antibodies
were not fit in the model since they did not appear in all
subjects during the time period examined, and when they did,
they appeared at a median time of 15 days later than the
anti-gp41 antibodies. We found in all cases, except for donor
9032, that including anti-gp41 antibody-mediated effects did
not improve the model fit (Table 3). Thus, it appears that for
the majority of patients the basic target cell-limited model is
the most compatible with the data; i.e., including the humoral
immune response involving either anti-gp41 IgG, IgM, or both
does not improve the model fit to the viral kinetics observed
for the first 40 days after T0. This suggests that early in AHI
either target cell limitation or cell-mediated responses play the
TABLE 2. Timing of immune complexes and free HIV antibodies relative to T0
Subject No. of daysafter T0




(OD values) IgG IC
c IgM ICc VLd
12008 2 0.181 0.017 — — 925
4 0.157 0.018 — — 24,194
9 0.173 0.014 32,833 25,389 5,631,550
14 1.795 0.114 130,556 162,222 6,486,240
16 9.528 0.795 132,778 89,056 2,296,060
21 6.063 0.997 1,344 778 26,311
23 4.646 0.872 — 2,350 17,425
9079 4 0.108 0.045 — — 56,508
6 0.135 0.037 — 989 731,600
11 2.839 0.618 788 9,944 584,913
13 10.763 1.186 190 652 2,170,000
19 4.169 0.610 — — 20,988
26 6.331 0.353 — — 3,594
9076 3 0.164 0.001 — — 50
3 0.155 0.000 — — 5,393
5 NT 0.039 — — 352
11 4.879 0.345 — — 697,960
14 17.241 0.958 3,256 1,489 507,740
19 17.241 0.121 — — 4,912
9015 0 0.171 0.030 — — 59
7 0.171 0.023 — 1,422 2,483,020
9 0.171 0.036 1,933 2,067 2,912,250
14 7.863 0.120 — 926 349,278
16 11.538 0.255 — — 276,354
9021 3 0.483 0.055 — — 50
1 0.793 0.069 — — 387
5 0.569 0.096 — 376 28,487
8 0.138 0.085 — 4,922 404,218
12 0.716 0.213 — 7,156 520,471
15 2.345 1.251 1,314 29,833 5,417,090
9077 2 0.153 0.071 — — 1353
6 0.198 0.078 — — 79,235
11 0.135 0.091 — — 798,590
13 0.432 0.093 8,494 5,670 400,900
18 8.793 1.682 — — 1,114,040
25 9.514 1.267 — — 40,369
28 10.225 0.861 — — 17,838
a For the ABBOTT anti-HIV-1/2 EIA, the positivity cutoff is 1.0. Boldface indicates a positive value. NT, not tested.
b Values were calculated as described in Materials and Methods; values that were 0.1 and at least threefold above baseline were considered positive, as indicated
by boldface.
c IC, immune complex. A dash indicates 200 copies/ml by quantitative real-time PCR of immune complexes; boldface indicates positive values.
d HIV-1 RNA PCR Ultra, Quest Diagnostics, Lyndhurst, NJ.
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predominant role in controlling VL. In support of this notion,
no statistically significant association was identified between
the magnitude of anti-gp41 IgG and the VL decay rate. There
was also no statistically significant association identified be-
tween the VL decay rate and the time to the first elevation of
antibody.
Ontogeny of CD4i antibodies, CD4bs antibodies, and non-
neutralizing cluster II (MPER) gp41 antibodies in plasma
donors and in three additional AHI cohorts followed 6 to 12
months after transmission. For analysis of antibody responses
during the downslope of VL after transmission, we studied 12
clade B subjects from Trinidad/Tobago with heterosexual
transmission, 14 acute clade C subjects from South Africa (the
CAPRISA cohort) (24), and 10 clade B AHI subjects from the
United States (3 untreated subjects and 7 subjects on antiret-
roviral treatment; CHAVI 001 cohort). The acute-phase viral
kinetics and distribution of samples used in this study from a
subset of subjects in the Trinidad/Tobago and the CHAVI 001
cohort are shown in Fig. S1 in the supplemental material.
Subsequent to the initial B-cell response to HIV-1 infection
that produces anti-gp41 antibodies, the anti-HIV-1 Env B-cell
response eventually broadened to include other Env specific-
ities. Antibodies that bind to the MPER gp41 (cluster II anti-
bodies) (63) can be either neutralizing (e.g., MAbs 2F5, Z13,
and 4E10) or nonneutralizing (e.g., MAbs 267D, 126-6, and
13H11) (reviewed in reference 2). Whereas nonneutralizing
anti-gp41 MPER antibodies are commonly made in 80% of
infected subjects (2), broadly neutralizing MPER antibodies
are rarely made (27). CD4i antibodies bind at or near the
coreceptor binding site and potently neutralize HIV-1 gener-
ally only after soluble CD4 is added to the in vitro neutralizing
assay (15) due to the inability of a bivalent antibody to fit into
the coreceptor binding site. Broadly neutralizing CD4bs anti-
bodies are also rarely made (38). Previously described assays
for these three anti-Env specificities were used to probe plasma
donor panels (followed up to 40 days after T0) as well as to
probe serial plasma samples from selected subjects in the clade
C CAPRISA (24) and clade B Trinidad/Tobago (8) acute
HIV-1 infection cohorts (both followed 6 to 12 months after
transmission). As mentioned, CD4i, CD4bs, and nonneutral-
izing cluster II gp41 antibodies were not made during the first
40 days after T0 (Table 1). In the CAPRISA and Trinidad/
Tobago AHI cohorts, CD4i antibodies, CD4bs antibodies, and
nonneutralizing cluster II MPER gp41 antibodies arose at ap-
proximately the same time, from 5 to 10 weeks postenrollment
into the acute infection study (see Fig. S3 in the supplemental
material) (2).
Evaluation of anti-HIV-1 heterologous tier 1 and autolo-
gous neutralizing antibody responses in plasma donors and
CAPRISA and Trinidad AHI cohorts. As previously men-
tioned, using the highly neutralization-sensitive tier 1 clade B
virus, SF162.LS, no neutralizing antibody responses were de-
tected in plasma donors for up to 40 days after T0. Heterolo-
gous tier 1 neutralizing antibodies against HIV-1 MN were
present in the Trinidad/Tobago cohort as early as 8 weeks after
infection (see Table S1 in the supplemental material) and were
likely primarily V3-directed since autologous V3 peptides com-
peted for heterologous HIV-1 MN neutralization (M. L.
Greenberg, unpublished data). Autologous neutralizing anti-
bodies arose after a median of 32 weeks from the time of
transmission in the Trinidad/Tobago clade B cohort (G. D.
Tomaras and M. L. Greenberg, unpublished data) and at a
mean of 19 weeks following transmission in the CAPRISA
clade C cohort (24).
DISCUSSION
In this study we show that the initial B-cell response to the
transmitted/founder virus is to HIV-1 gp41 Env, with responses
to gp120 delayed by an additional 14 days. Mathematical mod-
eling of the effects of initial IgM and IgG gp41 antibodies on
viral kinetics in the plasma donor cohort revealed little if any
effect of the initial antibody response on control of acute phase
plasma viremia.
The timing and specificity of the initial antibody response to
HIV-1 Env were of interest for several reasons. First, the
window of opportunity for a vaccine to extinguish the trans-
mitted or founder strain of HIV-1 is likely quite short, and the
timing of this window will vary from subject to subject depend-
ing on the time of establishment of the latent pool of CD4 T
cells. That postexposure prophylaxis does not protect beyond
24 h after simian immunodeficiency virus challenge in rhesus
FIG. 6. Ontogeny of complement binding antibodies during acute HIV-1 infection in times post-T0. Two representative patients (Pt) from the
eclipse phase cohort (6240 and 6246) that had detectable HIV-specific antibodies were assessed for complement activation with an early virus
isolate, HIV QH0692, and a laboratory-adapted isolate, HIV SF162.
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macaques (18) implies that the window of opportunity may be
10 days or less in humans (61). Moreover, early appearance of
evidence of systemic inflammation and acute phase reactants
in plasma at 5 to 7 days before T0 (B. Kessler, A. McMichael,
and P. Borrow, personal communication), as well as the ap-
pearance of plasma analytes of apoptosis 7 days after T0 (22),
adds support to this short estimated window of opportunity for
vaccine efficacy. Given that a narrow window of time might
exist for antibodies to be protective and given that immune
complexes only arise 18 days after transmission (8 days after
T0 with an estimate of time from transmission to T0 of a mean
of 10 days; range, 7 to 21 days) (7, 11, 14, 21, 40, 52), then the
first antibody response to HIV-1 is quite delayed relative to
when it optimally should occur to either extinguish or control
transmitted/founder HIV-1 strains.
Our study is the first demonstration of virion-antibody com-
plexes during the initial phase of viremia in acute HIV-1 infection.
Previous work looking at later times in acute infection did not find
immune complexes early in HIV-1 infection but, rather, found
immune complexes only in chronic infection (16). The presence
of these early immune complexes during acute infection raises the
question of whether antibody-coated virus remains infectious;
work is ongoing to determine the infectivity of opsonized virus
(D. C. Montefiori, G. D. Tomaras, and B. F. Haynes, unpublished
FIG. 7. (A) No hypergammaglobulinemia observed within the first 40 days of acute infection. Total antibody levels were measured at the first
HIV-negative (HIV)sample and the last sample in the panel (HIV). The median concentration across panels is indicated. (B) Detection of
rheumatoid factor (RF) during HIV acute phase viremia. IgM rheumatoid factor was measured using standard ELISA detection with positive
rheumatoid factor controls. VL is measured in RNA copies/ml. Pt, patient.
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data). However, it is well established that the likelihood of HIV-1
transmission is highest during acute infection. Taken together,
these data suggest an HIV-1 evasion strategy wherein the trans-
mitted/founder virus initially induces antibodies that bind virions
yet are nonneutralizing. Further work is needed to decipher the
specificities and avidities of the antibodies in the immune com-
plexes present at 8 days after T0 to determine if these initial
antibody responses could be protective if a vaccine were able to
prime for an early boost of the timing and magnitude of these
antibodies after HIV-1 transmission.
That the initial B-cell response to Env selectively recognized
gp41 was also of interest. Li et al. recently demonstrated that
when broadly neutralizing antibodies do appear, they appear late
and include antibodies against the CD4bs on gp120 (38). While
there are broadly neutralizing epitopes on gp41 in the MPER,
like broadly neutralizing CD4bs antibodies, neutralizing antibod-
ies to the MPER are rarely made, and when they are made,
require 1 year after transmission to arise (X. Shen and G. D.
Tomaras, unpublished observations). Thus, the host-pathogen in-
teractions occurring during and immediately after transmission
result in a delay in recognition of the HIV-1 envelope by host B
cells until after the latent pool of infected cells is likely estab-
lished.
Polyclonal activation of B cells occurs in chronic HIV-1 infec-
tion and as well has been reported in early HIV-1 infection (47).
We found no polyclonal hypergammaglobulinemia in plasma do-
nors but did find plasma rheumatoid factor in 30% of subjects.
Thus, polyclonal B-cell activation does occur early on, as signaled
by the detection of this autoantibody, likely indicating triggering
of CD5 B cells that are producers of rheumatoid factor auto-
antibodies (26).
Also of interest is that there was heterogeneity in the pattern
FIG. 8. Modeling the effect of antibody on plasma viremia in AHI with the target cell-limited model. The target cell-limited model is the
best-fitting model for the plasma donors studied except 9032. For 9032, a model with virion clearance enhanced by the sum of anti-gp41 IgM and
IgG provides the best fit.
TABLE 3. Comparison of the ability of the target cell-limited model and variants including anti-gp41 antibodies to fit early
plasma VL kinetic data
Subject
no.
Fit of the indicated model (P value)a
Best-fitting modelCE model: ID model CDE model
IgG IgM IgGIgM IgG IgM IgGIgM CDE IgG CDE IgM CDE IgG IgM
6240 0.320 0.326 0.266 0.975 0.977 0.975 0.975 0.975 1.000 Target cell limited
6246 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 Target cell limited
9032 0.004 0.006 0.001 0.005 0.006 0.006 0.89 0.011 0.923 CE or ID
9077 0.567 0.998 0.687 0.604 0.998 0.623 0.722 0.998 0.991 Target cell limited
9079 0.992 0.994 0.960 0.998 0.649 0.992 0.964 0.070 0.598 Target cell limited
12008 0.566 0.607 0.590 0.648 0.546 0.657 1.000 1.000 1.000 Target cell limited
a The VL data from each donor was fit using the target cell-limited model and models that incorporated the effects of anti-gp41 IgG or IgM and IgG plus IgM. CE,
clearance enhanced; ID, infectivity diminished; CDE, cell death enhanced. The models with antibody effects include one additional parameter, which when set to zero
reduces the model to the target cell-limited model. An F-test was used to determine if any of the models including antibody fit the VL data significantly better than
the target cell-model. The table gives the P values computed from the F-test.
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of Ig class switching seen following HIV-1 transmission. We
have shown that the simultaneous appearance of anti-HIV
IgM, IgG, and IgA is unlikely to be due to the presence of
immune complexes that mask detection of antibodies because
immune complexes appeared at the same time as free antibody
in half of the subjects. Other potential explanations for simul-
taneous appearance of IgM, IgG, and IgA anti-HIV-1 antibod-
ies in plasma include prior exposure to HIV-1 and primary
T-cell-independent B1 and marginal zone B-cell responses to
HIV-1 following transmission (9).
If the simultaneous appearance of IgM, IgG, and IgA to Env
and Gag represents prior exposure of 60% of subjects to
HIV-1 antigens and represents a rapid secondary response to
HIV-1 full infection, then an atypical aspect of the response is
that the putative “secondary” response occurs at exactly the
same time as the primary IgM response (day 13.0 after T0)
occurs in those with sequential appearance of anti-Env and
anti-Gag IgM, IgG, and IgA. If the simultaneous response is
indeed secondary from prior HIV-1 exposure, then it should
occur approximately 7 days earlier than observed. Thus, we
believe it is unlikely that the simultaneous appearance of IgM
and class-switched antibodies in plasma in more than two-
thirds of AHI subjects studied indicates prior exposure to
HIV-1.
Soon after transmission in both humans and nonhuman pri-
mates when infection is established, there is a severe depletion
of CD4 T lymphocytes (4, 57) that could lead to a lack of
sufficient CD4 help for stimulation of B-cell responses. The
early depletion of CD4 CCR5 T lymphocytes with massive
apoptosis could, in addition to altering T-cell homeostasis, lead
as well to suppression of an initial protective B-cell response
(22, 43). Thus, elicitation of initial T-cell-independent antibody
responses, in the setting of T-cell depletion, could be respon-
sible for simultaneous appearance of IgM, IgG, and IgA anti-
HIV-1 antibodies. A similar T-cell-independent pattern with
simultaneous appearance of IgM, IgG, and IgA anti-pneumo-
coccal antibody occurs following pneumococcal vaccine (9).
It was important to model both the antibody timing and the
VL dynamics to determine any salutary or detrimental effects
of early antibody responses on control of plasma viremia. As a
null model we used a simple target cell-limited model that
includes no effect of humoral or cellular immune responses
(53). We found that for five of the six plasma donors for which
we had VL data extending past the VL peak and out to day 40
after T0, this model gave good agreement with the VL data.
Nonetheless, we asked if the fit could be improved by using a
model that incorporated any of a variety of known functional
effects of antibody. Not surprisingly, it was only for the one
plasma donor, 9032, for which the target cell-limited model did
not give good agreement with the VL data that an improve-
ment was seen when antibody was included in the model.
Interestingly, this donor was unusual in that the peak VL was
significantly lower than in the other donors (3.4  104 copies/
ml). Taken together, these analyses suggested that for most
donors, early antibody had little functional consequence for
the control of viremia.
If early antibody induced by the transmitted virus had any
antiviral effects, then antibody-induced viral escape should be
detected after the appearance of complexed or free antibody in
plasma. In this regard, Keele et al. (35) have recently se-
quenced the transmitted founder virus for the plasma donors
studied in this report and found that virus sequences at 14 days
after T0 conformed to a model of random viral evolution, thus
showing no evidence of early antibody-induced selection.
For HIV-1, functional consequences of antibody binding could
include virus neutralization on T lymphocytes or macrophages
(31, 32), ADCVI/antibody-dependent cellular cytotoxicity, com-
plement-mediated neutralization, antibody Fc-mediated effector
functions, virolysis, and/or inhibition of transcytosis. A recent
study (29) suggested that the concentrations of antibodies medi-
ating the different antiviral functions may be an important con-
sideration for complete virus elimination since Fc receptor-bind-
ing function requires higher antibody concentrations than are
required for virus neutralization. In addition, antibody- and com-
plement-mediated virion lysis can develop in acute infection and
can correlate with plasma VL during the acute stage of infection
(33). This antiviral activity did not correlate with neutralizing
antibodies and is thought to be an antiviral component of non-
neutralizing antibodies. Dendritic cells are positioned in mucosae,
where they are thought to be one of the first cell types to help
establish infection (reviewed in reference 62). It will be important
to determine whether the very earliest antibodies elicited in acute
HIV-1 infection can block HIV-1 infection in dendritic cells at
mucosal surfaces.
From the present study, it is clear that the initial B-cell
response to the transmitted/founder virus does not control
initial virus levels during the first 40 days of infection. How-
ever, we cannot rule out that some antibody specificities elic-
ited after virus transmission may affect a subset of virions but
are not substantial enough to significantly affect plasma vire-
mia at the time they appear. A critical question is whether
these types of nonneutralizing antibodies could be protective if
present before infection or, alternatively, if completely differ-
ent types of inhibitory antibodies will need to be induced by
future HIV-1 vaccines. Autologous neutralizing antibodies tar-
get envelope variable loops (46, 49, 50, 60) that can arise long
after any window of opportunity to extinguish HIV-1 has
passed. Thus, an effective HIV-1 vaccine will need to induce
antibodies prior to infection that bind native virion envelope
molecules and lead as well to maturation of a rapid secondary
neutralizing antibody response within the first week after trans-
mission.
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